BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
BridgeBio (Nasdaq: BBIO) announced that it will release its second quarter 2026 financial results and business update after the market closes on Monday, August 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio (Nasdaq: BBIO) announced that it will release its second quarter 2026 financial results and business update after the market closes on Monday, August 10, 2026. The company will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
According to BridgeBio, investors can access a live webcast of the presentation via the “Events & Presentations” page in the Investors section of its website, with a replay available for 30 days. Participants must register online through the provided webcast link. The company also highlights its focus on developing medicines for genetic conditions using a decentralized hub-and-spoke R&D model.
Details
News Market Reaction – BBIO
On Aug 3, the day this news came out, BBIO closed 0.16% below the previous close.
Data tracked by StockTitan Argus for the Aug 3 session.
Key Figures
- Reporting period
- second quarter 2026
- Financial results and business update
- Results release date
- August 10, 2026
- After market close
- Conference call time
- 4:30 pm ET
- August 10, 2026
- Webcast replay
- 30 days
- Available following the event
Previous Earnings date Reports
-
Announced first-quarter results and commercial updates scheduled for May 7
-
Announced fourth-quarter and full-year results scheduled for February 24
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its second quarter 2026 financial results and business update after the market closes on Monday, August 10, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
Participants may access the webcast by registering online using the following link, here.
About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.